BioRestorative Therapies (BRTX) Long-Term Deferred Tax (2016 - 2024)

BioRestorative Therapies' (BRTX) quarterly Long-Term Deferred Tax came in at $22381.0 in Q2 2024, up 134.65% on a QoQ basis from $9538.0 in Q1 2024.

BioRestorative Therapies (BRTX) Long-Term Deferred Tax (2016 - 2024) Analysis & Trends

BioRestorative Therapies (BRTX) has 6 years of Long-Term Deferred Tax data on file, last reported at $22381.0 in Q2 2024.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $22381.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $22381.0 (changed N/A YoY) and the FY2020 annual result came in at $14.1 million, up 17.36% from the prior year.
Long-Term Deferred Tax advanced to $22381.0 in Q2 2024, from $9538.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $14.1 million in Q4 2020 to a low of $9538.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	BioRestorative Therapies	1.94 Mn	-1.02 Mn	17,964.00

Download Data